Ratopati English
भाद्र २०७८

3rd COVID-19 vaccine dose boosts immunity tenfold: Israeli study

JERUSALEM, September 17: The third vaccine dose against COVID-19 increases the immune protection from infection tenfold, the Israeli Ministry of Health said on Thursday. The ministry said that a new Israeli study, published in the New England Journal of Medicine, examined the effectiveness of the third dose among those over the age of 60, who received the booster shot in August. The tenfold protection is compared to those who received only two doses at least five months ago. The study was conducted by a team of multidisciplinary researchers from the health ministry, the Weizmann Institute of Science, the Hebrew University of Jerusalem, the Technion, the Sheba Medical Center and the KI Research Institute, it said. "The data from Israel indicate high efficacy of Pfizer's third booster dose in preventing COVID-19 infection and serious illness," the ministry noted. Israel began vaccinating its population with the third vaccine dose on Aug. 1, as the Delta variant was spreading in the country and the effectiveness of the first two doses eroded. To date, nearly 3 million Israelis have received the third jab. The researchers found that 12 days after receiving the third shot, the rate of infections was more than 10 times lower among those who received the booster shot than those did not. This means that if the chance of those vaccinated with two doses to get infected with the Delta variant is about 50 percent compared to the unvaccinated, a booster dose lowers the risk to 5 percent, or raises the immune defense to 95 percent, the researchers concluded.

पूर्ण विवरण

सम्बन्धित सामग्री

India's daily COVID-19 caseload rises to 21,566

NEW DELHI, July 21: India's daily COVID-19 caseload on Thursday breached the 21,000 mark, officials said. According to federal health ministry data released Thursday morning, 21,566 new cases of COVID-19 were reported during the past 24 hours, taking the total tally to 43,825,185 in the country. With the reporting of fresh cases, India's active caseload currently stands at 148,881. The country also logged 45 related deaths during this period, which has pushed the overall death toll to 525,870 since the beginning of the pandemic, the ministry said. The daily positivity rate has risen to 4.25 percent and the weekly positivity rate was recorded at 4.51 percent, the ministry data showed. The ministry said so far 43,150,434 people have been successfully cured and discharged from hospitals, of whom 18,294 were discharged during the past 24 hours. According to the federal health ministry, the cumulative COVID-19 vaccination coverage in the country has exceeded 2 billion doses on Sunday and until Thursday morning, 2,009,191,969 doses were administered. The Indian government is presently focusing on promoting booster doses as the uptake for the third dose has been low. The drive to provide free booster doses of the COVID-19 vaccine to all adults at government centers has begun last week. According to officials, the exercise is aimed at improving the booster dose coverage among the people in wake of the detection of new variants. A super-transmissible subvariant of the omicron strain, known as BA.5, is fueling a fresh increase in infections, and a super contagious omicron mutant (BA.2.75) that has begun to gain ground in the country has worried health officials, which may be able to spread rapidly and get around immunity from vaccines and previous infections. Meanwhile, so far over 871 million COVID-19 tests have been conducted across the country. A cumulative total of 871,160,846 samples have been tested up to July 20, the Indian Council of Medical Research (ICMR) said Thursday. Out of these 507,360 tests were conducted on Wednesday alone.

Ratopati English आषाढ २०७९

India's COVID-19 daily caseload comes down to 16,935

NEW DELHI, July 18: After four straight days of reporting over 20,000 new cases a day, India's COVID-19 daily caseload on Monday came down to 16,935, officials said. According to health ministry data released on Monday morning, 16,935 new cases of COVID-19 were reported during the past 24 hours, taking the total tally to 43,767,534 in the country, and the active caseload currently stands at 144,264. India also logged 51 COVID-19-related deaths during this period, which has pushed the overall death toll to 525,760 since the beginning of the pandemic, the ministry said. With the increase in cases, the daily positivity rate stood at 6.48 percent and the weekly positivity rate was recorded 4.58 percent, the ministry data showed. The ministry said 43,097,510 people have been successfully cured and discharged from hospitals, of whom 16,069 were discharged during the past 24 hours. According to the health ministry, the cumulative COVID-19 vaccination coverage in the country exceeded 2 billion doses as 2,000,461,095 doses have been administered until Monday morning. The detection of a highly contagious Omicron mutant, BA.2.75, has begun to gain ground in India. There are fears that the new mutant may be able to spread rapidly and get around immunity from vaccines and previous infections. The Indian government has focused on promoting booster doses as the uptake for the third dose has been low. The drive to provide free booster doses of COVID-19 vaccine to all adults at government centers began on Friday. Meanwhile, so far over 869 million COVID-19 tests have been conducted across the country. Out of these 261,470 tests were conducted during the past 24 hours, the health ministry said.

Ratopati English आषाढ २०७९

Here is what you need to know about COVID-19 booster doses

Do you need extra shots of the vaccine for COVID-19 if you are fully vaccinated?  Most people who are fully vaccinated against the coronavirus are relatively protected from severe illness and death from COVID-19. However, even highly effective vaccine’s immunity often fades over time. Early studies on vaccines that use mRNA to protect against coronavirus, such as those conducted by Pfizer and Moderna, have shown that they work regardless of the virus variant (such as alpha, beta, or delta). A new vaccine, called a booster, a few months after the first dose can help make the vaccine more effective, research suggests.  In case of Pfizer-BioNTech Who has to get a booster? Everyone (12 years and older) When to get a booster? At least five months after finishing your number one COVID-19 vaccination series Which booster? Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines) are favored in most situations.Teens 12–17 years antique may also simplest get a Pfizer-BioNTech COVID-19 vaccine booster. In case of Johnson & Johnson’s Janssen* Who needs to get a booster? Adults 18 years and older When to get a booster? At least 2 months after receiving your J&J/Janssen COVID-19 vaccination Which booster must you get? Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines) are desired in most* situations What else does research say about COVID-19 boosters? Boosters are only a kind of vaccine, and scientists already recognise that vaccines are presently the excellent protection in opposition to COVID-19, mainly its maximum critical effects. That’s why it’s critical to get vaccinated proper away in case you qualify, as maximum human beings five and older do.Research additionally has discovered that, in general, antibodies from vaccines decline over time.Higher antibody degrees from vaccines appear to make the common individual much less probably to get unwell from the coronavirus (vaccine efficacy).Booster pictures of mRNA coronavirus vaccines (Pfizer and Moderna) boom antibodies with the aid of using approximately 10 times.Boosters can offer you similarly safety in opposition to the Omicron variation. Early information indicates that this version is extra transmissible than different variants. (Source : https://www.cdc.gov) Nepal started giving COVID-19 vaccine booster recently as coronavirus infections surged because of the unfold of the Omicron variant. The booster dose has been limited to frontline employees by the Health Ministry which will gradually be provided elderly in coming months. Nepal, a herbal buffer among China and India, has double-vaccinated 39.9% of its 30 million population in a marketing campaign that started early last year. The authorities have banned big public gatherings and urged one and all to strictly follow COVID-19 safety protocols. Authorities have additionally made it obligatory for the general public to provide evidence of complete vaccination to apply for public offerings.

Ratopati English पौष २०७८

Govt begins administering additional COVID-19 doses to elderly

KATHMANDU, December 16: The government has begun administering additional doses of COVID-19 vaccine to people older than 60 years old. The National COVID-19 Vaccination Advisory Committee has already recommended the government to administer the additional doses to elderly, according to Chairman of the committee, Dr Ramesh Kanta Adhikari. Those elederly who had received two shots of Verocell vaccine will receive an additional dose to boost their immunity.  Likewise, the shots will also be administered to people with compromised immunity who have already received both shots of the vaccine, according to Sagar Dahal, chief of the Family Welfare Division. “The government has already begun administering the additional doses of COVID-19 vaccines from some of the vaccination centers in the Kathmandu Valley,” Dahal added. Similarly, the government has decided to inoculate the Moderna COVID-19 vaccine to children aged between 12 to 17 from December 19 to 29. The vaccination will be administered in schools in 57 districts across the country. Also, the government will soon begin administering booster doses of COVID-19 to the public once the 50 percent of total eligible population receives at least one shot of COVID-19 vaccine.  So far, 47 percent of the total eligible population has been fully vaccinated against COVID-19 vaccine in the country. To maintain vaccine equality, the World Health Organization has prohibited the inoculation of booster doses before administering COVID-19 vaccine to at least 50 percent of the total eligible population. So far, Nepal has administered COVID-19 vaccine to as many as 20,995,536 people. Of them, 19,629,621 have received their first shots while 93,65,915 have received both shots, according to the Ministry of Health and Population.

Ratopati English कार्तिक २०७८

Govt preparing to administer COVID-19 booster shots in Nepal, Who can receive it?

Ratopati English कार्तिक २०७८

Govt administering Pfizer COVID-19 vaccine from today: Things to know

KATHMANDU, November 14: The government is administering the Pfizer vaccines against COVID-19 in Nepal from Sunday.  The vaccine will be administered to people with chronic diseases and who are older than 12 years old. According to Sagar Dahal, chief of the Immunization Section under the Department of Health Service, the Pfizer vaccine, received in a grant from the COVAX facility, will be administered to more than 50,000 people with chronic diseases. Those receiving the first dose will be administered the second dose within 21 to 28 days of receiving their first dose. Earlier, Nepal received 100,620 doses of Pfizer COVID-19 vaccines from COVAX. It has been made mandatory to possess a medical report of chronic disease issued by hospitals or medics to receive the vaccine. The vaccination drive will be conducted in 24 vaccine centers including eight in Kathmandu Valley and 16 out of the valley. Who can receive the vaccine? 1) Those who underwent heart surgery and heart patients 2) Kidney patients 3) Cancer patients 4) Lungs patients 5) Those who underwent any sort of organ transplant 6) High blood pressure and diabetes patients 7) Those with compromised immunity 8) Those suffering from brain diseases Vaccine centers for Pfizer vaccination in Kathmandu Valley: 1) Bir Hospital 2) TU Teaching Hospital 3) Civil Hospital 4) Sahid Gangalal Hospital 5) Bhaktapur Cancer Hospital 6) Patan Hospital 7) Sahid Dharmabhakta National Transplant Center 8) Birendra Sainik Hospital Vaccination centers outside of the valley 1) Mechi Hospital 2) BP Koirala Institute of Health Sciences 3) Janakpur Hospital 4) BP Koirala Memorial Cancer Hospital 5) Pokhara Academy of Health Sciences 6) Lumbini Provincial Hospital 7) Bheri Hospital 8) Koshi Hospital 9) Gajendra Narayan Singh Institute of Health Sciences 10) Dadeldhura Hospital 11) Rapti Institute of Health Sciences 12) Karnali Provincial Hospital 13) Seti Hospital 14) Dhulikhel Hospital  15) Dhaulagiri Hospital 16) Narayani Hospital Possible side effects of Pfizer COVID-19 vaccine - swelling, pain and redness in arm - headache, fever and chills - muscles and joints pain -loss in appetite and nausea - tiredness These symptoms will last only for two to three days after receiving the vaccine, according to the health ministry. To reduce pain and discomfort where the shot is given, the Center for Disease Control and Prevention of the United States of America recommends: - Applying a clean, cool, wet washcloth over the area - Using or exercising your arm To reduce discomfort from fever - Drinking plenty of fluids - Dressing lightly

Ratopati English आश्विन २०७८

Things to know about Pfizer COVID-19 vaccine being administered in Nepal from Sunday

Ratopati English आश्विन २०७८

U.S. approves new booster of COVID-19 vaccines, "mix and match" dose

WASHINGTON, Oct. 20: The U.S. Food and Drug Administration (FDA) on Wednesday authorized COVID-19 booster doses of Moderna and Johnson & Johnson, and approved "mix and match" booster dose for currently available approved COVID-19 vaccines. The agency authorized the use of a single booster dose of the Moderna COVID-19 vaccine at least 6 months after completion of the primary shots to people 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2. As for the Johnson & Johnson booster dose, the FDA authorized the use of a single booster dose at least 2 months after completion of the single-dose primary regimen to individuals 18 years of age and older. A single booster dose of any of the available COVID-19 vaccines may be administered as a "mix and match" booster dose following completion of primary vaccination with a different available COVID-19 vaccine, according to the FDA. For instance, a person who got a Johnson & Johnson vaccine could receive one from Moderna or Pfizer-BioNTech as a booster. "The available data suggest waning immunity in some populations who are fully vaccinated," said Acting FDA Commissioner Janet Woodcock in a statement. "The availability of these authorized boosters is important for continued protection against COVID-19 disease." The decision came after an FDA advisory committee voted last week to recommend authorizing Moderna and Johnson & Johnson's COVID-19 booster doses. In September, the FDA authorized the first booster shots for the Pfizer-BioNTech COVID-19 vaccine, allowing a single booster dose of the Pfizer-BioNTech vaccine be administered at least 6 months after completion of the primary series to individuals 65 years of age and older, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2. A recent study of the "mix and match" approach funded by the U.S. National Institutes of Health found no safety concerns using different vaccines as a booster. The study found that people who received the Johnson & Johnson vaccine produced stronger antibody levels after they got booster shots made by Moderna or Pfizer-BioNTech, compared to boosters from Johnson & Johnson.

Ratopati English आश्विन २०७८

Malaysia takes first delivery of China's CanSino COVID-19 vaccine

KUALA LUMPUR, August 20: The first batch of the single-dose COVID-19 vaccine developed by Chinese company CanSino Biologics arrived in Malaysia on Friday, boosting the country's capability in the fight against the pandemic.      The first batch, comprising some 200,000 finished products, is part of a total of 3.5 million doses that have been ordered by Malaysia, the Science, Technology and Innovation Ministry said in a brief statement.      This supply will be able to further intensify the National COVID-19 Immunization Program especially in low access areas and in turn help Malaysia to achieve immunity targets, the statement said.      Malaysia conditionally approved emergency use of the vaccine in June. The COVID-19 vaccines developed by China's Sinopharm and the vaccines made by the Chinese biopharmaceutical company Sinovac Biotech have also received approval.      Among them, Sinovac's Coronavac finished vaccines imported from China and the locally fill-and-finish products have been used in Malaysia's national immunization program.      Malaysia has been ramping up its vaccination drive which started in February. As of Thursday, 54 percent of the population has received at least one dose of vaccine and 36 percent are fully vaccinated.

Ratopati English श्रावण २०७८

New batches of Chinese COVID-19 vaccines arrive in Indonesia

JAKARTA, April 30: New batches of COVID-19 vaccines produced by Chinese pharmaceutical companies arrived at Indonesia's Soekarno-Hatta Airport on Friday, an Indonesian official said.     "Today, 6 million doses of bulk COVID-19 vaccine from Sinovac Biotech Ltd and 482,400 ready-to-use vaccines from the China National Pharmaceutical Group (Sinopharm) have arrived," Minister of Communications and Informatics Johnny Plate said.     Indonesia has received a total of 65.5 million doses of bulk COVID-19 vaccine from Sinovac, as well as 8.448 million doses of ready-to-use vaccines from Sinovac, Sinopharm, and AstraZeneca through the COVAX Facility initiated by the World Health Organization.     The bulk from Sinovac that arrived Friday will be brought to the state-company PT Bio Farma office to be processed into ready-to-use vaccines.     Meanwhile, the vaccine produced by Sinopharm will be used for a mutual vaccination scheme locally known as "Gotong Royong", where companies or legal entities can arrange the COVID-19 vaccine rollout for their employees for free to help the country achieve herd immunity faster.     Indonesia's Food and Drug Administration (BPOM) has just issued an emergency use authorization (EUA) for the Sinopharm vaccine.     "We are announcing that an emergency use authorization has been given for a vaccine produced by the Beijing Biological Products Institute under Sinopharm," chief of BPOM Penny Lukito said Friday.

Ratopati English चैत्र २०७७

Privacy

Download